CBFB and acute myeloid leukemia: Notably, rearrangements of RUNX1‐RUNX1T1 (OR = 5.025, [1.762‐14.329], P = .003) or CBFB‐MYH11 (OR = 20.285, [4.121‐99.848], P < .001), which were commonly referred to as core binding factor AML (CBF‐AML), were independently associated with the occurrence of PTR in multivariate analysis (Table 3).